Pamdeca LLC


Overview

A preclinical stage immuno-oncology start-up pursuing a novel approach - activation of the natural cancer-killing program in macrophages. Our first-in-class drugs will complement and enhance immune checkpoint inhibitors - the new immuno-oncology drugs giving hope to terminal cancer patients, but hampered by low response rates and rapid development of resistance to therapy. Our innovative IP is licensed from Northwestern University.

Management Team

CEO

Victor Shifrin

20+ years of R&D/clinical development/management in oncology and inflammation; Eisai USA, Scriptgen, Surface Logix, CombinatoRx.

CSO

Jack Henkin

20+ years of drug development; Anticancer Peptides Project Leader at Abbott, Abbott’s Scientist of the Year, 2003; 100+ scientific papers, reviews, and book chapters; Co-inventor of IP.

Head of R&D

Olga Volpert

20+ years of cancer research; Internationally recognized expert on cancer biology, angiogenesis, and tumor microenvironment; 88 publications (Science, Nature Medicine, Cancer Cell, Cancer Research); Co-inventor of IP.